Kiniksa (KNSA) PT Raised to $44 at JMP Securities

Go back to Kiniksa (KNSA) PT Raised to $44 at JMP Securities

Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology

September 15, 2018 8:00 AM EDT

- Single-doses were well-tolerated and showed reduction in pruritus -

- Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis -

HAMILTON, BERMUDA, Sept. 15, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today presented... More

Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology

September 15, 2018 8:00 AM EDT

- Single-doses were well-tolerated and showed reduction in pruritus -

- Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis -

HAMILTON, BERMUDA, Sept. 15, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today presented Phase 1a/1b... More